High-Throughput Dried Blood Spot (HT-DBS) Technologies in SARS COV-2 Serology and Vaccinology

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: Nicholas J. Mantis
Organization: WADSWORTH CENTER
Fiscal Year: 2022
Award: $592,301
Funding agency: National Cancer Institute

Project Summary
As the COVID-19 pandemic continues to spread across the United States it is imperative that we implement
technologies to screen large swaths of the population for the presence of antibodies to SARS-CoV-2.
Serological surveillance not only affords a measure of virus exposure within a community at large but also
provides information necessary to predict outbreak dynamics. Furthermore, as our understanding of how
humoral factors contribute to controlling (and possibly exacerbating) COVID-19, it will be essential to have
methods in place to measure the “quantity” and “quality” of antibodies associated with both natural SARS-CoV-
2 exposure and candidate SARS-CoV-2 vaccines. This U01 proposal seeks to advance the use of dried blood
spots (DBS) in conjunction with a Luminex-based microsphere immunoassay (MIA) to enable high-throughput
(HT) population-wide serological surveillance for SARS-CoV-2. Specifically, the proposal will expand the HT-
DBS assay to capture the breadth and complexity of SARS-CoV-2 antibody responses following natural
infection, and develop a high-throughput competitive immunoassay (CIA) as a surrogate measure of SARS-
CoV-2 neutralizing antibody titers in DBS. The proposed platform technologies to be developed at the
Wadsworth Center will contribute directly to NCI’s mission to “… develop, validate, improve and implement
serological testing and associated technologies…” to address the COVID-19 pandemic.

Terms: <19S Gamma Globulin><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><7S Gamma Globulin><Address><Antibodies><Antibody Response><Antibody titer measurement><Antigens><Assay><Bioassay><Biologic Assays><Biological Assay><Blood><Blood Reticuloendothelial System><Blood Serum><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 antibody><COVID-19 antigen><COVID-19 crisis><COVID-19 epidemic><COVID-19 exposure><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 immunity><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 screening><COVID-19 surveillance><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 immunity><COVID19 pandemic><COVID19 public health crisis><COVID19 screening><COVID19 surveillance><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><CoV-2><CoV2><Communities><Disease Outbreaks><Employee><Essential employee><Essential person><Essential personnel><Essential staff><Essential worker><Food Services><General Population><General Public><Goals><HCV/HIV><HIV and HCV><HIV and hepatitis C><HIV-HCV><HIV/HCV><HIV/Hepatitis C><Health><Health Care Providers><Health Personnel><Healthcare Providers><Healthcare worker><Hordeolum><Human><IgA><IgG><IgM><Immunity><Immunoassay><Immunoglobulin A><Immunoglobulin G><Immunoglobulin M><Individual><Infection><Laboratories><Liquid substance><Measures><Methodology><Methods><Microbeads><Microspheres><Mission><Modeling><Modern Man><NCI Organization><NIAID><National Cancer Institute><National Institute of Allergy and Infectious Disease><New York><Outbreaks><Population><Principal Investigator><Proteins><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 antigen><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 immunity><SARS-CoV-2 pandemic><SARS-CoV-2 screening><SARS-CoV-2 surveillance><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 antigen><SARS-CoV2 epidemic><SARS-CoV2 exposure><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Saliva><Sampling><Schools><Science><Sensitivity and Specificity><Serology><Serology test><Seroprevalences><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Spottings><Stye><Technology><Testing><Time><United States><Virus><Work><Wuhan coronavirus><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody titering><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><base><co-infection><cohort><coinfection><convalescent plasma><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 antigen><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 immunity><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 screening><coronavirus disease 2019 surveillance><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><first responder><fluid><hCoV19><health care personnel><health care worker><health provider><health workforce><healthcare personnel><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunogen><immunological status><improved><liquid><medical personnel><member><minimally invasive><nCoV2><neutralizing antibody><neutralizing mAb><neutralizing monoclonal antibodies><non-human primate><nonhuman primate><pre-clinical><preclinical><saliva sample><salivary sample><sample collection><serology assay><serology surveillance><serology survey><serosurveillance><serosurvey><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 screening><severe acute respiratory syndrome coronavirus 2 surveillance><specimen collection><treatment provider><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus><vaccine study><vaccine trial><vaccinology>